Full video transcriptClick to expand
Auto-generated transcript of @healing.endo.meno's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So responding to this question about testosterone post and she's using testosterone cream
- 0:05but now she's having hair loss and this can happen if your testosterone converts to DHT.
- 0:12Not many women do but in my experience I always convert it to DHT even prior to having
- 0:17hormone replacement therapy.
- 0:19But there are ways to control it.
- 0:21So when you start your testosterone cream and you are experiencing any breakouts or any
- 0:26hair loss, one thing you can do is lower your dose, one but talk to your provider first,
- 0:33and two you can skip your dose.
- 0:35Those things might help you get rid of those on one side effects.
- 0:39But let's say you are feeling good with that dose, it's just the side effects that are affecting
- 0:43your life now.
- 0:44Well, you can take either a spiralic tone which is prescribed and it's also aduretic so it
- 0:50helps if you have any bloating from the beginning using testosterone and finasterate.
- 0:54And the endostrate is very common medication that is prescribed for hair loss.
- 0:59And let's say that you can't afford that right now and you just want to add something quick
- 1:03and you want to just go over the counter, then Sopometto is a product that you can find
- 1:08at any pharmacy and it's pretty safe.
- 1:11You just have to make sure you read the labels to know how much you have to take it for
- 1:14how long.
- 1:16And if you feel like none of this has help, then it's time maybe to talk to your provider
- 1:22about that delivery method.
- 1:24When I was on creams, I was breaking out a lot.
- 1:26So when I switched to injections, that stopped.
- 1:29And I think it happened because the way it's been delivered now is subsoil maybe differently.
- 1:34Maybe I'm not converting as much to DHT.
- 1:37So if you're having these side effects, you can check your DHT levels, DHT blockers, or
- 1:43change the delivery method.
- 1:44And if you have any questions, let me know.
- 1:47Thanks for watching.
- 1:48Follow and like.
- 1:49Bye-bye.
Testosterone therapy for perimenopause: separating signal from hype
Quick answer
Androgenic alopecia in women using exogenous testosterone is typically mediated through DHT conversion via 5-alpha reductase, with genetic susceptibility determining individual response. First-line management involves dose titration with serum DHT monitoring, followed by pharmacologic intervention with spironolactone or finasteride if dose reduction is insufficient or not desired. Delivery method changes may affect local skin DHT concentrations but do not reliably reduce systemic DHT levels, and this decision should be made with a prescriber based on full clinical context.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Testosterone therapy for perimenopause: separating signal from hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Testosterone therapy for perimenopause: separating signal from hype is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Testosterone therapy for perimenopause: separating signal from hype" from Cynthia✨Menopause & Endo Coach. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Androgenic alopecia in women using exogenous testosterone is typically mediated through DHT conversion via 5-alpha reductase, with genetic susceptibility determining individual response.
The reason this review is not generic is the source wording and the canonical claim label "trt replying to mealsmindfulnessandmore thank you for following." In this clip, the useful excerpt is: "So responding to this question about testosterone post and she's using testosterone cream but now she's having hair loss and this can happen if your testosterone converts to DHT." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Androgenic alopecia in women using exogenous testosterone is typically mediated through DHT conversion via 5-alpha reductase, with genetic susceptibility determining individual response.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Androgenic alopecia in women using exogenous testosterone is typically mediated through DHT conversion via 5-alpha reductase, with genetic susceptibility determining individual response. First-line management involves dose titration with serum DHT monitoring, followed by pharmacologic intervention with spironolactone or finasteride if dose reduction is insufficient or not desired. Delivery method changes may affect local skin DHT concentrations but do not reliably reduce systemic DHT levels, and this decision should be made with a prescriber based on full clinical context.
- DHT-driven hair loss from testosterone therapy is real: 5-alpha reductase converts testosterone to DHT in skin and hair follicles, and genetically susceptible women are at higher risk regardless of delivery method.
- Dose reduction is the first-line step before adding any blocker. Serum DHT testing before escalating treatment helps confirm the mechanism is actually DHT excess.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- DHT-driven hair loss from testosterone therapy is real: 5-alpha reductase converts testosterone to DHT in skin and hair follicles, and genetically susceptible women are at higher risk regardless of delivery method.
- Dose reduction is the first-line step before adding any blocker. Serum DHT testing before escalating treatment helps confirm the mechanism is actually DHT excess.
- Finasteride is teratogenic and requires a prescriber. It should not be self-initiated, particularly in women who may become pregnant, and the creator was correct to frame it as a prescription medication.
- Spironolactone needs monitoring. It affects potassium and blood pressure, and the diuretic effect is real but secondary to its anti-androgenic mechanism in this context.
- Saw palmetto (Serenoa repens) showed only modest benefit in a 2021 randomized trial (Wessagowit et al., Journal of Dermatological Treatment). It is a reasonable low-risk option to discuss with a provider, not a reliable standalone treatment.
- Injectable testosterone does not clearly reduce DHT conversion compared to creams at the systemic level. A 2010 study (Borst et al., Clinical Endocrinology) found injectable testosterone esters raised serum DHT significantly.
- Any change to testosterone dose, formulation, or addition of a DHT blocker should involve the prescribing provider, not just over-the-counter supplementation or self-adjusted dosing.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @healing.endo.meno actually say?
The creator responded to a viewer experiencing hair loss while using testosterone cream, attributing it to testosterone converting to DHT (dihydrotestosterone). She suggested lowering the dose, skipping doses, using spironolactone or finasteride if prescribed, or trying over-the-counter saw palmetto. She also shared that switching from cream to injections resolved her own breakouts, speculating that subcutaneous delivery may reduce DHT conversion.
The advice was structured around a reasonable decision tree: reduce dose first, add a DHT blocker second, change delivery method third. She was clear about telling viewers to talk to their provider before adjusting doses, which is the right call. She also mentioned checking DHT levels, which is genuinely useful guidance.
Does the science back this up?
Mostly, yes, though some of the nuance gets lost. The DHT conversion pathway is real and well-documented, and it is a legitimate cause of androgenic alopecia and acne in women using testosterone. The evidence on whether delivery method actually changes DHT conversion rates is thinner than she implies.
Testosterone does convert to DHT via the enzyme 5-alpha reductase, and this can trigger androgenic side effects in genetically susceptible women. A 2019 paper by Glaser and Dimitrakakis in Maturitas confirmed that androgenic side effects including hair loss are reported in a subset of women on testosterone therapy, with dose being the primary modifiable factor. Spironolactone is a legitimate androgen receptor blocker used off-label for this, and finasteride is a genuine 5-alpha reductase inhibitor. Both have real clinical use here. Saw palmetto (Serenoa repens) has limited but real evidence, including a small 2021 randomized trial by Wessagowit et al. in Journal of Dermatological Treatment, showing modest benefit in androgenic alopecia, but effect sizes are small.
What did they get wrong (or right)?
The delivery method claim deserves scrutiny. She says switching from cream to injections stopped her breakouts, reasoning that "maybe I'm not converting as much to DHT." That is a reasonable hypothesis but not well-supported by direct evidence. Transdermal testosterone can produce localized high concentrations at the application site, which may drive local DHT production in the skin, but systemic DHT conversion is not clearly lower with injections. Some data actually suggest injections produce higher peak DHT levels due to supraphysiologic testosterone spikes. A 2010 study by Borst et al. in Clinical Endocrinology noted that testosterone esters administered by injection produced significant DHT elevation.
She also mispronounced spironolactone as "spiralic tone" and saw palmetto as "Sopometto," which is a minor issue but could confuse viewers trying to look these up. She correctly framed spironolactone as a diuretic and noted it may help with bloating, which is accurate. She got the finasteride recommendation right and the dosing caution on saw palmetto is reasonable consumer advice.
What should you actually know?
If you are a woman on testosterone therapy experiencing hair loss, the mechanism she describes is real: DHT is the likely culprit, and dose reduction is the first sensible step. But the path from there is not a simple over-the-counter fix.
- Spironolactone requires a prescription and monitoring. It affects potassium levels and blood pressure, and should not be self-initiated.
- Finasteride carries a pregnancy warning and is teratogenic. It is sometimes used in postmenopausal women but requires a prescriber who knows your full history.
- Saw palmetto has limited evidence. It is not a substitute for medical management if hair loss is significant.
- Checking your serum DHT level is genuinely useful before adding blockers, as she suggests. Some women on low-dose testosterone will have normal DHT and the hair loss may have a different cause entirely.
- The injection versus cream DHT claim is not settled. Do not switch delivery methods solely based on this reasoning without talking to your prescriber about the actual tradeoffs for your situation.
The creator is sharing personal experience alongside real clinical concepts, which is a useful combination, but the personal experience parts should not be treated as generalizable evidence.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Cynthia✨Menopause & Endo Coach · TikTok creator
1.8K views on this video
Replying to @mealsmindfulnessandmore Thank you for following me! Hope this helps! 🙏🏼 #testosteronetherapy #hormones #perimenopause #fypシ #trt
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about dht-driven hair loss from testosterone therapy?
DHT-driven hair loss from testosterone therapy is real: 5-alpha reductase converts testosterone to DHT in skin and hair follicles, and genetically susceptible women are at higher risk regardless of delivery method.
Dose reduction is the first-line step before adding any blocker. Serum DHT testing before escalating treatment helps confirm the mechanism is actually DHT excess?
Dose reduction is the first-line step before adding any blocker. Serum DHT testing before escalating treatment helps confirm the mechanism is actually DHT excess.
What does the video say about finasteride?
Finasteride is teratogenic and requires a prescriber. It should not be self-initiated, particularly in women who may become pregnant, and the creator was correct to frame it as a prescription medication.
What does the video say about spironolactone needs monitoring. it affects potassium?
Spironolactone needs monitoring. It affects potassium and blood pressure, and the diuretic effect is real but secondary to its anti-androgenic mechanism in this context.
What does the video say about saw palmetto (serenoa repens) showed only modest benefit in a?
Saw palmetto (Serenoa repens) showed only modest benefit in a 2021 randomized trial (Wessagowit et al., Journal of Dermatological Treatment). It is a reasonable low-risk option to discuss with a provider, not a reliable standalone treatment.
What does the video say about injectable testosterone does not clearly reduce dht conversion compared to?
Injectable testosterone does not clearly reduce DHT conversion compared to creams at the systemic level. A 2010 study (Borst et al., Clinical Endocrinology) found injectable testosterone esters raised serum DHT significantly.
Not medical advice. This video was made by Cynthia✨Menopause & Endo Coach, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.